X4 Pharmaceuticals, Inc. (XFOR)

Trade XFOR now with
10/8/2020 8:11:17 AM X4 Pharmaceuticals Says Fast Track Designation Granted By FDA To Mavorixafor
5/14/2020 9:16:08 AM X4 Pharma Announces Data From Phase 2 Open-Label Extension Trial Of Mavorixafor In WHIM Syndrome
2/12/2020 8:40:58 AM X4 Pharmaceuticals Says USPTO Issued United States Patent No. 10,548,889
12/30/2019 8:32:55 AM X4 Initiates Phase 1b Trial Of Mavorixafor In Combination With Ibrutinib For Waldenstrm's Macroglobulinemia Treatment
11/27/2019 2:32:48 AM XFOR Prices Offering At $12/Shr
11/25/2019 4:05:21 PM X4 Pharmaceuticals Announces Proposed Public Offering
9/18/2019 8:32:23 AM X4 Pharma Appoints Renato Skerlj As SVP Of Research And Development
11/27/2018 7:17:08 AM X4 Pharmaceuticals To Merge With Wholly-owned Subsidiary Of Arsanis In An All-stock Transaction
11/9/2018 8:05:33 AM Arsanis Q3 Net Loss $10.9 Mln Vs. Net Loss $11.6 Mln Last Year
8/13/2018 8:10:58 AM Arsanis Q2 Net Loss $12.1 Mln Or $0.85 Per Share
6/28/2018 7:12:27 AM Arsanis Announces Discontinuation Of Its Phase 2 Clinical Trial Of ASN100
6/28/2018 7:10:38 AM Arsanis, Trading Expected To Resume At 7:30 AM ET